Modified Low-Dose Triiodo-L-thyronine Therapy Safely Improves Function Following Myocardial Ischemia-Reperfusion Injury by Viswanathan Rajagopalan et al.
ORIGINAL RESEARCH
published: 12 April 2017
doi: 10.3389/fphys.2017.00225
Frontiers in Physiology | www.frontiersin.org 1 April 2017 | Volume 8 | Article 225
Edited by:
Gaetano Santulli,
Columbia University, USA
Reviewed by:
Clara Crescioli,
Foro Italico University of Rome, Italy
Consolato Sergi,
University of Alberta, Canada
*Correspondence:
Viswanathan Rajagopalan
vrajagop@nyit.edu
Specialty section:
This article was submitted to
Clinical and Translational Physiology,
a section of the journal
Frontiers in Physiology
Received: 02 February 2017
Accepted: 29 March 2017
Published: 12 April 2017
Citation:
Rajagopalan V, Zhang Y, Pol C,
Costello C, Seitter S, Lehto A,
Savinova OV, Chen Y-f and
Gerdes AM (2017) Modified
Low-Dose Triiodo-L-thyronine Therapy
Safely Improves Function Following
Myocardial Ischemia-Reperfusion
Injury. Front. Physiol. 8:225.
doi: 10.3389/fphys.2017.00225
Modified Low-Dose
Triiodo-L-thyronine Therapy Safely
Improves Function Following
Myocardial Ischemia-Reperfusion
Injury
Viswanathan Rajagopalan 1, 2*, Youhua Zhang 2, Christine Pol 2, Clifford Costello 2,
Samantha Seitter 2, Ann Lehto 2, Olga V. Savinova 2, Yue-feng Chen 2 and A. Martin Gerdes 2
1Department of Basic Sciences, New York Institute of Technology-College of Osteopathic Medicine, Jonesboro, AR, USA,
2Department of Biomedical Sciences, New York Institute of Technology-College of Osteopathic Medicine, Old Westbury, NY,
USA
Background: We have shown that thyroid hormones (THs) are cardioprotective and
can be potentially used as safe therapeutic agents for diabetic cardiomyopathy and
permanent infarction. However, no reliable, clinically translatable protocol exists for TH
treatment of myocardial ischemia-reperfusion (IR) injury. We hypothesized that modified
low-dose triiodo-L-thyronine (T3) therapy would confer safe therapeutic benefits against
IR injury.
Methods: Adult female rats underwent left coronary artery ligation for 60 min or sham
surgeries. At 2 months following surgery and T3 treatment (described below), the rats
were subjected to functional, morphological, and molecular examination.
Results: Following surgery, the rats were treated with T3 (8 µg/kg/day) or vehicle
in drinking water ad libitum following IR for 2 months. Oral T3 significantly improved
left ventricular (LV) contractility, relaxation, and relaxation time constant, and decreased
beta-myosin heavy chain gene expression. As it takes rats ∼6 h post-surgery to begin
drinking water, we then investigated whether modified T3 dosing initiated immediately
upon reperfusion confers additional improvement. We injected an intraperitoneal bolus
of T3 (12 µg/kg) upon reperfusion, along with low-dose oral T3 (4.5 µg/kg/day) in
drinking water for 2 months. Continuous T3 therapy (bolus + low-dose oral) enhanced
LV contractility compared with oral T3 alone. Relaxation parameters were also improved
compared to vehicle. Importantly, these were accomplished without significant increases
in hypertrophy, serum free T3 levels, or blood pressure.
Conclusions: This is the first study to provide a safe cardiac therapeutic window and
optimized, clinically translatable treatment-monitoring protocol for myocardial IR using
commercially available and inexpensive T3. Low-dose oral T3 therapy supplemented
with bolus treatment initiated upon reperfusion is safer and more efficacious.
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INTRODUCTION
Despite advancements, cardiovascular diseases remain the No.
1 disease burden worldwide (Dzau, 2016). In the United
States, coronary artery diseases contribute to almost half of the
cardiovascular deaths and myocardial ischemia-reperfusion (IR)
injury remains a major challenge. Although IR is less injurious
than permanent occlusion of the culprit vessel(s), IR also
results in significant oxidative stress and functional compromise.
The challenge for researchers is to identify interventions that
maximize recovery of reperfusedmyocardium. Thyroid hormone
(TH)-mediated cardioprotection has been demonstrated using
various models of cardiovascular disorders (Rajagopalan and
Gerdes, 2014; Gerdes and Ojamaa, 2016). Both thyroid hormones
(THs), Thyroxine (T4) and triiodo-L-thyronine (T3) are secreted
systemically by the thyroid gland and perform numerous
physiological functions on heart and other systems. Free T3 is
the active form of T3 and is a clinically important biomarker.
Thyroid-stimulating hormones (TSHs) stimulate TH release and
regulate their serum levels. Hsu et al. (1995) has previously shown
that T3 supplementation after IR in a pig model significantly
enhanced acute post-ischemic left ventricular (LV) functional
recovery. However, these results have not been followed long
term or translated into patient care. The apparent perception
that THs may be risky for clinical therapy is largely based on
problematic TH analog studies (Stamler, 1977; Young et al., 1984;
Goldman et al., 2009) where the analog was contaminated with
active L-thyroxine or excessive dosing likely occurred. In this
regard, we request the readers to refer to detailed published
reviews by our group and others (Pingitore et al., 2010; Gerdes,
2015; Gerdes and Ojamaa, 2016; Jabbar et al., 2017).
To overcome these challenges, robust translatable protocols
that are both safe and efficacious are needed. Recent animal
data from our lab and others’ suggests that fear of TH
overtreatment may actually be causing harm by withholding
treatment from many patients who will likely benefit by TH
replenishment (Weltman et al., 2014, 2015; Gerdes and Ojamaa,
2016). Although T4 is used for the treatment of patients with
primary hypothyroidism, T3, T4, or combination treatment have
been proposed for the treatment of hypothyroidism secondary
to cardiovascular disorders (Gerdes and Iervasi, 2010; Suh and
Kim, 2015). Though the issue is far from being resolved, T3
may be preferred since the conversion mechanisms of T4 into
T3 are known to be impaired in non-thyroidal illness syndrome
(Pingitore et al., 2012). T3 largely by-passes this potential
problem of bioavailability by direct application of the active
form of TH (Weltman et al., 2013). We have shown that short-
term treatment of T3 protected cardiomyocytes against ischemia-
induced apoptosis (Chen et al., 2008). In addition, short-term
T3 treatment in patients with ischemic and non-ischemic HF
was well-tolerated and resulted in improved cardiac function
and attenuated neurohormonal activation (Hamilton et al., 1998;
Pingitore et al., 2008). However, long-term protection is unclear
in humans.
Recently, we demonstrated that oral T3 treatment for 2
months following myocardial infarction (MI) improved cardiac
function and rhythm without significant cardiac adverse effects
(Rajagopalan et al., 2016). Additional information is needed
regarding therapeutic T3 treatment of IR. We hypothesized that
similar protection will be conferred following myocardial IR.
This is the first study to demonstrate that a modified low-dose
oral T3 therapy in IR is safer for the heart and more efficacious in
not only a dose-dependent, but also, a time-dependent manner.
MATERIALS AND METHODS
Ethical Approval
This study was approved by the Institutional Animal Care and
Use Committee of the New York Institute of Technology College
of Osteopathic Medicine (NYIT-COM) and is in compliance
with the “Guide for the Care and Use of Laboratory Animals”
(National Institutes of Health Publication No. 85–23, Revised
1996). Based on ARRIVE guidelines (NC3Rs), adult female
Sprague-Dawley rats aged 11 weeks old were purchased from
Harlan (Indianapolis, IN, USA), acclimatized and housed up to 3
per cage. They were kept on a 12-h light–dark cycle with standard
rat chow and water provided ad libitum. Permanent ligation
MI procedure was performed by the same surgeon as described
before (Chen et al., 2013; Rajagopalan et al., 2016).
Ischemia-Reperfusion Injury
Rats were randomly assigned to a sham-operated group or an IR
group. The operating surface was prepared by disinfecting the
area with 70% ethanol. All surgical instruments were sterilized
with a hot bead sterilizer before surgery and in between
individual rat surgeries. These instruments include: surgical
scissors, forceps, needle holders, and a chest retractor. Heating
pad using a circulating water T/Pump (Gaymar Industries Inc.,
Orchard Park, NY) was used to maintain the body temperature of
the animal at 37 ± 1◦C. An electric shaver was used to shave the
fur from the neck and chest areas. Shaved areas were scrubbed
and disinfected with betadine solution followed by wiping the
area with 70% alcohol. Anesthetized animal was placed in a
supine position on the heating pad. Endotracheal intubation
was performed and mechanical ventilation was achieved by
connecting the endotracheal tube to a Kent Scientific ventilator
cycling at 70 breaths per minute and a tidal volume of 1.0ml
per 100 gram body weight. IR was induced by 60min ligation of
the left anterior descending coronary artery. At the end of the
ischemic period, the knot around the blood vessel was loosened
and unrestrained reperfusion was allowed. The silk suture was left
in situ, the chest retractor was removed and the ribs were drawn
together using a 5-0 silk suture with a continuous suture pattern.
Sham-operated animals underwent the same procedure except
that the suture was tied loosely around the coronary artery. Tidal
volume of the ventilator was temporarily increased to expand the
lungs and expel air from the chest. The skin was closed using 5-0
silk in a continuous suture pattern.
Following extubation, intramuscular Buprenorphine
analgesia was administered. IR rats were randomly assigned to
an IR+V (vehicle) group and an IR+T3 group. T3 (0.08 µg/ml)
was dissolved in ethanol/glycerol and added to drinking water
for a total duration of 2 months (mo). This provided a dose
of 8 µg/kg/d based on daily water consumption (Rajagopalan
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et al., 2016) and serum TH feedback inhibition response from
previous studies (Weltman et al., 2014). Vehicle was used in
rats not treated with T3 using the aforementioned diluents. In a
subsequent cohort of IR rats, we further repeated studies of oral
T3 (at 0.045 µg/ml or 4.5 µg/kg/d) along with an intraperitoneal
(i.p.) bolus of T3 (12 µg/kg) upon reperfusion. Based on
results of the first experiment, the oral T3 dose was reduced for
optimization.
At 2 mo post-IR, blinded, standard isoflurane-anesthetized
(3% induction, 1.5%maintenance) cardiac catheterization studies
were followed by body weight measurements and terminal
experiments (surgical plane isoflurane anesthesia followed by
diastolic cardiac arrest). This included blood collection for serum
TH levels and tissue collection for histology and molecular
studies.
Echocardiography
Two-dimensional echocardiograms (GE Vivid 7 Dimension,
Horten, Norway; M12L transducer) were obtained from LV
short-axes to visualize the extent of infarction in the immediate
post-op period (Chen et al., 2013). Animals that did not develop
infarcts between 30 and 50% (Pfeffer et al., 1985) and those that
did not survive for more than 48 h (immediate post-op period)
were excluded (Rajagopalan et al., 2016). Subsequently, at 2-mo
post-surgery, structural assessments were performed.
Serum Thyroid Hormone Levels
LV blood samples were collected, separated into serum by
centrifugation, and stored at −80◦C until assayed. Serum
TH levels were measured using commercial enzyme-linked
immunosorbent assay (ELISA) kits (TSH: ALPCO, Salem, NH,
USA; T3, FT3, T4, FT4: Monobind Inc., Lake Forest, CA,
USA) according to manufacturer specifications and prior studies
(Weltman et al., 2014; Rajagopalan et al., 2016).
Hemodynamics
LV hemodynamic data were obtained under anesthesia by right
carotid arterial catheterization using a 1.9F SciSense pressure-
volume catheter (Transonic Scisense Inc., London, Ontario). The
catheter tip was advanced through the aorta into the LV to study
arterial and LV pressures, change in pressures over time (dP/dt)
and other hemodynamic parameters. The data were acquired and
analyzed by LabScribe (iWorx Systems, Inc., Dover, NH).
Electrophysiology Studies
Electrophysiological studies were performed using techniques
successfully employed for rat myocardial ischemic and thyroid
models (Zhang et al., 2013, 2014; Rajagopalan et al., 2016). Under
anesthesia, a 1.6F octopolar Millar electrophysiology catheter
(EPR-802,Millar Instruments, Inc., Houston, Texas) was inserted
through right jugular vein and advanced into the right atrium
to record atrial electrograms. Standard surface ECG lead II and
3 right atrial electrocardiograms were displayed and recorded
using a PowerLab data acquisition system (ADInstruments,
Colorado Springs, CO). Burst pacing containing 200 impulses at
50 Hz was used to induce atrial tachyarrhythmias (ATA). ATA
were defined as rapid atrial activations with varying electrogram
morphology lasting >0.5 s. The mean ATA duration based on 5
such tests was used to reflect the ATA substrate in each animal.
Histology
Hearts were arrested in diastole by injection of 0.2 M potassium
chloride via the LV apex followed by rapid transfer to ice-
cold phosphate buffered saline. Subsequently, aortas were
cannulated with an 18G gavage needle to allow coronary
perfusion with ice-cold phosphate buffered saline containing
0.2% 2,3-butanedione monoxime. Fat and aorta were trimmed
and discarded, hearts blotted, and chamber weights quickly
documented. The transverse mid-slice of the LV with septum
was dissected. Paraformaldehyde-fixed 5 µm thick LV tissue
sections were stained with Masson’s Trichrome stain. Images
were acquired using Olympus BX53 microscopes and transmural
infarct characteristics were analyzed using Image-Pro plus
(Media Cybernetics, Bethesda, MD) or Image J (National
Institutes of Health, Bethesda, MD) programs.
Real-Time Quantitative PCR
RNA isolation and real time PCR was performed following
similar protocols as before (Rajagopalan et al., 2016). Briefly,
RNA was isolated using TRIzol reagent followed by RNA
purification using PureLink RNA mini kit and DNaseI kit
(Invitrogen, Carlsbad, CA). RNA quantity and quality were
determined and validated using NanoDrop 1000 (Thermo
Scientific, Wilmington, DE). Equal amounts of RNA from
each sample were converted to cDNA using RT2 First
Strand Kit (Qiagen Inc., Valencia, CA). Gene expression was
evaluated using SYBR green/ROX detection (Supplementary
Table) and Applied Biosystems StepOnePlus (Life Technologies
Corporation, Carlsbad, CA). GAPDH (Glyceraldehyde 3-
phosphate dehydrogenase) and beta-actin or Ppia (cyclophilin
A) were used as housekeeping control genes and expression data
analyzed using 2−11CT method.
Statistical Analysis
All data are expressed as means ± standard error, unless
otherwise noted. Data analysis was performed with GraphPad
Prism forWindows (GraphPad, San Diego, CA) and groups were
compared using student’s t-test or one-way analysis of variance
(ANOVA) followed by post-hoc tests. Fisher exact test was used
to compare the incidence of atrial tachyarrhythmias (ATA; Zhang
et al., 2013). A non-parametric Kruskal–Wallis test followed
by Dunn’s multiple comparison test was used to compare ATA
duration in the oral treatment groups. A value of P < 0.05 was
considered statistically significant.
RESULTS
Morphometric Changes Following Oral T3
Treatment
Although starting body weights were lower in the IR groups
[IR+V (O) and IR+T3 (O)] compared to Sham+V (O), all the
groups gained weights proportionately over time (Table 1). Two
months oral T3 treatment did not affect body weight, as there
was no difference between IR+V (O) and IR+T3 (O) groups.
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TABLE 1 | Cardiac remodeling in 2 mo IR rats after oral (only) T3.
Sham+V (O) IR+V (O) IR+T3 (O)
Body weight, peri-op (g) 232 ± 9 216 ± 7* 223± 16
Body weight, post-op (g) 273 ± 12 259 ± 12 258± 15
Heart weight (mg) 938 ± 108 997 ± 82 1,171± 212*§
Heart weight/BW (mg/g) 3.5 ± 0.5 3.8 ± 0.3 4.5± 0.6***§§
LV (+ septum) weight (mg) 654 ± 73 712 ± 49* 790± 49***§§
LV (+ septum) weight/BW (mg/g) 2.4 ± 0.3 2.7 ± 0.2** 3.1± 0.1***§§
Values are means ± SD; BW, body weight; LV, Left ventricular; RV, right ventricular; O,
Oral; V, Vehicle; IR, Ischemia-reperfusion; T3, Triiodo-L-thyronine; *p < 0.05, **p < 0.01,
***p < 0.001 vs. Sham+V; §p < 0.05, §§p < 0.01 vs. IR+V; n = 7 (Sham+V), n = 11
(IR+V), n = 9 (IR+T3).
IR tended to increase heart weight and significantly increased
LV weight (LV+septal weight) and LV weight to body weight
ratio compared to sham values. Oral T3 at 8 µg/kg/d following
IR further increased these parameters. Histologically, there was
no statistically significant difference in viable areas within infarct
segments between both IR groups (IR+V: 5.85 ± 0.89 mm2;
IR+T3: 5.27± 0.68 mm2; Supplementary Figure 1).
Serum Thyroid Hormone Levels Following
Oral T3
IR did not significantly alter serum thyroid profiles, except
increasing free T4 levels (Table 2). T3 treatment at 8 µg/kg/d
increased serum free T3 levels. Correspondingly, as expected,
T3 resulted in feedback inhibition of both T4 and TSH levels.
In addition, oral T3 treatment restored the free T4 levels
following IR.
Improvement in Cardiac Remodeling and
Function with Oral T3
Heart rate (HR) showed a mild increase following T3 treatment
with 8 µg/kg/d by echocardiography (Table 3). LV posterior
wall dimension following IR was significantly improved by
oral T3 treatment. While IR significantly impaired LV systolic
anterior wall thickness, internal dimensions and function, T3 did
not significantly affect these parameters. Cardiac catheterization
studies (Figures 1A–D) showed that IR resulted in impaired
contractility, as indicated by a reduction in maximal rate of
LV pressure development (dP/dtmax; Figure 1A; Supplementary
Figure 2). Oral T3 treatment restored this contractility index.
Similarly in IR, diastolic function was impaired, reflected by
a decrease in maximal rate of pressure decline (dP/dtmin;
Figure 1B) and an increase in LV relaxation time constant, tau
(Figure 1C). Both these parameters were significantly improved
following oral T3.
Investigating electrophysiological characteristics of IR hearts,
we found significant atrial arrhythmia in only one out of 11
vehicle-treated IR rats. Similar to the sham group, oral T3
treatment resulted in no arrhythmias.
Expression of Representative Genes
Following Oral T3
We investigated mRNA expression of representative genes
relevant to IR and thyroid signaling (Figure 2). As expected,
TABLE 2 | Serum thyroid hormone levels in 2 mo IR rats after oral (only) T3.
Sham+V (O) IR+V (O) IR+T3 (O)
Total T3 (ng/ml) 1.1 ± 0.05 1.1 ± 0.2 1.5± 0.65
Free T3 (pg/ml) 2.6 ± 1 3.1 ± 0.5 4.0± 0.9**§
Total T4 (ng/ml) 49 ± 6.8 45 ± 12 29± 11**§§
Free T4 (pg/ml) 8.9 ± 4.6 16 ± 3.4** 6.5± 4.8§§§
TSH (ng/ml) 1.7 ± 0.5 1.8 ± 0.8 0.4± 0.3**§§§
Values are means ± SD; O, Oral; V, Vehicle; IR, Ischemia-reperfusion; T3, Triiodo-L-
thyronine; T4, Thyroxine; TSH, Thyroid stimulating hormone; **p < 0.01, vs. Sham+V;
§p < 0.05, §§p < 0.01, §§§p < 0.001 vs. IR+V; n = 5–7 (Sham+V), n = 11 (IR+V); n = 9
(IR+T3).
TABLE 3 | Echocardiographic parameters in 2 mo IR rats after oral (only)
T3.
Sham+V (O) IR+V (O) IR+T3 (O)
Heart rate (bpm) 343 ± 13 344 ± 33 378 ± 43
LVPWs (mm) 2.7 ± 0.4 2.2 ± 0.6* 2.6 ± 0.3§
LVPWd (mm) 1.8 ± 0.3 1.7 ± 0.4 2.0 ± 0.2†
LVIDs (mm) 3.8 ± 0.7 6.4 ± 1.2*** 6.7 ± 1.6***
LVIDd (mm) 7.1 ± 0.5 8.6 ± 0.9** 8.9 ± 1.1**
LVAWd (mm) 1.7 ± 0.3 1.3 ± 0.3 1.4 ± 0.5
LVAWs (mm) 2.4 ± 0.6 1.5 ± 0.3** 1.6 ± 0.6**
FS (%) 46.7 ± 6.8 25.8 ± 6.5*** 25.8 ± 9.4***
EF (%) 82.4 ± 6.3 55.5 ± 10.8*** 54.6 ± 15.8***
Values are means± SD; LVPW, left ventricular posterior wall; LVAW, left ventricular anterior
wall; LVID, left ventricular internal diameter; FS, Fractional shortening; EF, Ejection fraction;
s, systole; d, diastole; O, Oral; V, Vehicle; IR, Ischemia-reperfusion; T3, Triiodo-L-thyronine;
*p < 0.05, **p < 0.01, ***p < 0.001 vs. Sham+V; §p<0.05, vs. IR+V; †p<0.05 vs. IR+V
(t-test); n = 7 (Sham+V), n = 11 (IR+V); n = 9 (IR+T3).
we found that beta myosin heavy chain (Myh7) expression
was significantly downregulated following oral T3 treatment.
Interestingly, β-site amyloid precursor protein cleaving enzyme 1
(Bace1) was increased following IR (p< 0.05) and returned close
to sham levels following oral T3. MMP-2 and TIMP-1 levels did
not significantly alter following T3 treatment (data not shown).
TIMP-1 increased following T3 (Sham+V: 0.0306± 0.006; IR+V:
0.0342 ± 0.005; IR+T3: 0.067 ± 0.011, p < 0.05 vs. IR+V &
Sham+V)
Early Initiation of Continuous T3 Treatment
Leads to Safer and Greater Cardiac
Performance
Our observations have revealed that it takes about 6 h post-
surgery for rats to start drinking water, and therefore, drug
intake (Rajagopalan et al., 2016). To avoid this delay in
availability of T3, we investigated whether administering a
bolus T3 dose immediately following IR is safe and could
result in enhanced cardiac performance. In a separate cohort
of IR rats, we administered 12 µg/kg T3 i.p. upon reperfusion.
Given that 8 µg/kg/d resulted in increased heart weight and
free T3 levels (preceding experiment), we reduced the oral
dose to 4.5 µg/kg/d, which was continued for 2 months
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FIGURE 1 | Hemodynamic changes after oral (only) T3 treatment. Oral T3 treatment following IR significantly enhanced (A) dP/dtmax, maximal rate of pressure
development, (B) dP/dtmin, maximal rate of pressure decline and (C) tau, τ, LV relaxation time constant. (D) ESP, LV End-systolic pressure is unaffected; V, Vehicle;
n = 7 (Sham+V), n = 11 (IR+V); n = 9 (IR+T3); **p < 0.01, ***p < 0.001 vs. Sham+V; §p < 0.05, §§p < 0.01 vs. IR+V.
following the i.p. treatment. We found that heart weights
and LV weights were not significantly increased following
this reduced T3 regimen (Figure 3) indicating no T3-induced
hypertrophy. While serum total T4 levels showed feedback
inhibition, the levels of serum free T3 were preserved
(Figure 4).
Compared to vehicle, continuous T3 treatment (bolus +
low-dose oral) resulted in significant increases in dP/dtmax, a
measure of cardiac contractility (Figure 5; Supplementary Figure
2). Tau decreased by 19% following continuous T3 treatment
(bolus + low-dose oral) and end-systolic pressures increased.
Importantly, the increase in dP/dtmax was greater than that
observed with oral T3 alone in the previous experiments in
Figure 1A (p < 0.05) using a slightly higher dose. Compared
to oral T3 (7.6 ± 1.5mmHg), end-diastolic pressures following
bolus + low-dose oral T3 (5.9 ± 0.84mmHg) treatment were
reduced, although not significant. There was no significant
difference in HR between vehicle-treated and continuous T3-
treated (bolus + low-dose oral) groups. Electrophysiological
studies showed that two out of nine vehicle-treated IR
rats developed significant inducible atrial arrhythmias (1.39
± 1.3 s) compared to none in the continuous T3-treated
group.
Expression of Long Non-coding RNAs
(lncRNAs)
Following IR, real-time qPCR-based lncRNA expression of H19
(0.0055± 0.004 vs. 0.0017± 0.001; p= 0.05) increased compared
to sham. Continuous T3 treatment (0.0041 ± 0.002) did not
significantly affect the expression levels compared to IR. There
were no statistically significant differences in expression of other
lncRNA targets including Tug1, Neat1, and Sra1 in this model
(data not shown).
DISCUSSION
The new findings of the study include: a modified low-dose
continuous oral T3 treatment-monitoring protocol significantly
improved IR myocardial deficits without significant cardiac
side effects. We also demonstrated a safe therapeutic window
below the threshold of inducing increased heart mass or heart
rate, information important in planning future clinical trials.
Timely reperfusion of the infarct-related coronary artery is
important for minimizing myocardial damage, infarct size,
morbidity, and mortality (Bagai et al., 2014). These studies
offer important new insight on key parameters including
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FIGURE 2 | Gene expression following oral (only) T3 treatment. Values are means ± SD; V, Vehicle; IR, Ischemia-reperfusion; T3, Triiodo-L-thyronine. Gene
expression was normalized using cyclophilin A. (A) Myh7, cardiac beta myosin heavy chains; (B) Thra, Thyroid hormone receptor alpha; (C) Thrb, Thyroid hormone
receptor beta; (D) Bace1, β-site amyloid precursor protein cleaving enzyme 1; *p < 0.05 vs. Sham+V (Anova, post-hoc); §p < 0.05 vs. IR+V (Anova, post-hoc);
†p < 0.05 vs. Sham+V (t-test); n = 5 per group.
cardiac safety, efficacy, timing, and frequency of TH treatment.
Together with our other studies in rat models of permanent
coronary ligation (Rajagopalan et al., 2016), diabetes mellitus
(Weltman et al., 2014), and hypertension (Weltman et al.,
2015), we have now determined that ∼3–6 µg/kg/day is a safe
and efficacious treatment window for rats fed ad lib. Doses
within this range offer significant improvements in cardiac
contractility, relaxation, rhythm, and gene expression profile.
Above this dose range, increases in HR and/or heart weight
become detectible, suggesting a safe upper limit for desired
treatment effects was reached. There was no evidence of any
adverse health effects in the first IR study reported here using
8 µg/kg/day T3. Our findings also document for the first
time, decreased atrial tachyarrhythmias in IR compared to MI
(Rajagopalan et al., 2016). We speculate this may be due to
lack of significant atrial dilation following IR compared to
MI.
We determined whether T3 supplementation begun
immediately upon reperfusion (IP bolus injection) provided
further improvements over delayed oral T3 treatment alone
(e.g., 6-h delay from commencement of drinking after surgery).
This combination strategy showed greater improvement in
cardiac contractility compared to oral treatment alone. This
demonstrates that TH-mediated myocardial protection in
the “early” reperfusion period is critical for preserving and
further enhancing cardiac performance. Since blood pressures
were not significantly altered (Supplementary Figure 3), these
changes are likely the result of direct effects of T3 on the
heart. These findings are supported by relevant studies in (i)
large mammals of transient regional myocardial ischemia and
Frontiers in Physiology | www.frontiersin.org 6 April 2017 | Volume 8 | Article 225
Rajagopalan et al. Triiodo-L-thyronine Protocol Safely Improves IR
FIGURE 3 | No significant hypertrophy following continuous T3 (bolus + low-dose oral). (A) Body weight; (B) Heart weight; (C) Heart weight to body weight
ratio; (D) LV weight; (E) LV weight to body weight ratio; Values are means ± SD; LV, Left ventricular plus septal; V, Vehicle; IR, Ischemia-reperfusion;
T3, Triiodo-L-thyronine (12 µg/kg bolus followed by 4.5 µg/kg/day); n = 8–9 (IR+V), n = 7 (IR+T3).
FIGURE 4 | Serum thyroid hormone levels in 2 mo IR rats after continuous T3 (bolus + low-dose oral). (A) Free T3 (1 mo); (B) Free T3 (2 mo); (C) Total T4
(1 mo); (D) Total T4 (2 mo); Values are means ± SD; V, Vehicle; IR, Ischemia-reperfusion; T3, Triiodo-L-thyronine; T4, Thyroxine; mo, month; ***p < 0.001,
****p < 0.0001; 1 mo: n = 5 (IR+V), n = 8–11 (IR+T3); 2 mo: n = 10–12 (IR+V), n = 11 (IR+T3).
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FIGURE 5 | Significant hemodynamic improvement after continuous (bolus + low-dose oral) T3 treatment. Continuous T3 treatment following IR using
combined peri-operative intraperitoneal and subsequent oral T3 treatment significantly improved (A) dP/dtmax, maximal rate of pressure development and (B)
dP/dtmin, maximal rate of pressure decline. (C) tau, τ, LV relaxation time constant partially decreased and (D) ESP, LV End-systolic pressure increased; V, Vehicle; n =
7 (Sham+V), n = 11 in (IR+V); n = 9 in (IR+T3); *p < 0.05, **p < 0.01 vs. corresponding IR+V groups; §p < 0.05, §§p < 0.01 between both IR+T3 groups.
reperfusion, (ii) transient global myocardial ischemia in patients
undergoing cardiac surgery on cardiopulmonary bypass, and (iii)
transient inadequate global myocardial perfusion in brain-dead
potential organ donors (Novitzky and Cooper, 2014). Following
administration of THs in these acute conditions, myocardial
dysfunction associated with loss of high-energy phosphates and
accumulation of tissue lactate was reversed. Although total T3
is frequently used, free T3, is now understood to be a clinically
important biomarker in cardiovascular disorders and is the
active form of the hormone (Iervasi et al., 2003; Fontana et al.,
2012; Cerillo et al., 2014; Kishi, 2015; Jankauskiene et al., 2016;
Wang et al., 2016). While 8 µg/kg/day showed increased serum
free T3 levels, 4.5 µg/kg/day did not, indicating that the lower
dose is both a safer cardiac dose and free T3 may be a clinically
relevant biomarker for monitoring during T3 therapy. Although
there was no further increase in salvaged myocardium despite
increased Timp1 (Kinoshita et al., 2014) compared to IR, T3
significantly enhanced cardiac functional performance along
with reduced beta myosin heavy chain levels. Other studies
have shown reduced infarct characteristics with THs (Forini
et al., 2014; Rajagopalan et al., 2016). However, compared to the
present study, they differ with nature of ischemia, duration of
infarction, duration of treatment, etc.
Numerous studies from our group and others have extensively
documented TH-mediated cardioprotective mechanisms. We
demonstrated that T3/T4 protects the heart and vascular system
via several mechanisms, viz., sarcomeric, thyroid, ion channels,
fibrosis, sympathetic, mitochondria, autophagy, growth factors,
cell structure, etc. (Liu and Gerdes, 1990; Tang et al., 2005; Chen
et al., 2012, 2013; Zhang et al., 2013; Weltman et al., 2014;
Rajagopalan et al., 2016). Myocardial contraction results from
coordinated cross-bridging of sarcomeric myosin heavy chains
and these are regulated by T3 at the promoter level (Kahaly and
Dillmann, 2005). In the present study, as demonstrated before
(Chen et al., 2013; Weltman et al., 2013, 2014), we found that
beta myosin heavy chain expression was significantly decreased
by oral T3. This indicates that the T3-mediated improvement in
cardiac function is at least partially mediated at the sarcomeric
level. T3 is also a negative regulator of the most abundant
cardiac TH receptor, Thra (Kahaly and Dillmann, 2005; Pantos
and Mourouzis, 2014), and our data showed a downward
trend in expression levels with oral T3. Ischemia contributes to
hypoperfusion and inflammation. One of the markers following
brain ischemia is increased Bace1, β-site amyloid precursor
protein cleaving enzyme 1 (Nural-Guvener et al., 2013; Sun et al.,
2015). Although Bace1 inhibition attenuates neuroinflammation
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(Neumann et al., 2015), its role in myocardial ischemia and
TH-mediated cardioprotection is unknown. We found that
Bace1 levels are increased in IR LV and oral T3 returned
them closer to control levels. This indicates that Bace1 may
be a potential target and worthy of future investigation. We
have previously shown that T3 protects cardiomyocytes against
ischemia-induced apoptosis via Akt signaling (Chen et al.,
2008). Others have also demonstrated role of oxidative stress
in subclinical hypothyroidism (Obradovic et al., 2016). Using
in vivo and isolated cardiomyocyte approaches, Forini et al.
(2014) recently showed that subcutaneous infusion of T3 restored
non-coding microRNA miR-30a expression, downregulated p53
and Bax, limited mitochondrial membrane depolarization and
decreased apoptosis and necrosis in the IR area at risk. Alongwith
short non-coding microRNAs, interest in the role of long non-
coding RNAs in cardiovascular health and disease has increased.
As was shown in mouse models of hypertrophic HF (Lee et al.,
2011) and human HF (Greco et al., 2016), we found that rat H19
lncRNA levels were increased following IR injury.
Limitations
As discussed elsewhere (Zhang et al., 2014), female rats were used
because they maintain a more stable body mass over time than
males, thus minimizing interpretation of heart weight alterations
related to this potential distractor. Females also have a higher
incidence of thyroid anomalies requiring TH replacement (Sara
et al., 2015). Since other studies have demonstrated TH-based
cardioprotective effects in males (Pantos et al., 2008; Henderson
et al., 2009), a different outcome would be unexpected. T3
treatment in a sham group was not included because producing
hyperthyroidism has been studied extensively and was not a
goal here (Gerdes et al., 1987; Venditti et al., 2002; Kuzman
et al., 2005; Weltman et al., 2012; Zhang et al., 2013). After
more than 30 years of examining myocyte remodeling using
the most accurate available methods (e.g., Coulter Channelyzer
analysis of isolated myocytes and direct measurement of isolated
myocyte length), we have found that LV mass changes exceeding
∼15% are generally needed to reach statistical significance in
myocyte remodeling parameters (Gerdes and Pingitore, 2014).
Since current data show values less than this limit, we did
not assess myocyte remodeling. Furthermore, as the goals of
the study centered on the heart, we did not study non-cardiac
effects. Long-term survival studies would be of future interest and
we anticipate beneficial effects with T3 treatment under serum
monitoring. Based on our experience from several hundred
consistent coronary ligation microsurgeries, we obtained only
representative transverse mid wall LV and not multiple LV
sections (Chen et al., 2008, 2013; Rajagopalan et al., 2016). This
is consistent with observations of others (Kanamori et al., 2011;
Eulalio et al., 2012).
CONCLUSIONS
The study provides a modified, treatment-monitoring protocol
for T3 treatment of myocardial IR injury in rats. This information
should provide helpful guidance for further clinical studies. We
optimized both the dose and timing and have shown that lower
doses of oral T3 delivered from the onset of IR injury provide
the greatest benefits with no obvious cardiac side effects. T3 is
commercially available and inexpensive. The translational nature
of this study provides encouraging supportive data for ongoing
(http://ponte-project.eu/) and future clinical trials.
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